ArticleMolecular cancer therapeutics2014

Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia.

Monica L Guzman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.